NCT06421311View on ClinicalTrials.gov

Observational Study of Muscle Invasive Urothelial Carcinoma Participants Treated With Adjuvant Nivolumab in France

TerminatedOBSERVATIONAL
Enrollment

176

Participants

Timeline

Start Date

July 30, 2024

Primary Completion Date

April 4, 2025

Study Completion Date

April 4, 2025

Conditions
Urothelial Carcinoma
Interventions
DRUG

nivolumab

According to approved product label (France)

Trial Locations (1)

75002

Local Institution - 0001, Paris

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT06421311 - Observational Study of Muscle Invasive Urothelial Carcinoma Participants Treated With Adjuvant Nivolumab in France | Biotech Hunter | Biotech Hunter